Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Avantor, Inc.NYSE: AVTR

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes turns negative

Q2 FY2026 effect of forex changes was -$1M, compared with $14.8M a year earlier. Trailing-twelve-month effect of forex changes was -$8M.

Context

  • Effect of forex changes amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near -$1M or moves back toward the trailing-twelve-month quarterly average of -$2M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1M-79.6% QoQ
Last fiscal yearDec 2025
$19.7M+191.6% YoY
LTMJun 2026
-$8M-205.3% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-106.8%——
1 year+191.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
19.7M USD
Year-over-year change
+191.6%

Effect of Forex Changes vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -205.3% is the 8th highest of 9, against a peer median of -136.1%.
  • Effect of forex changes amounts to 0.1% of revenue for AVTR, versus a peer median of 0.4%.
AVTR Competitors
Effect of Forex Changes for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$63M USD-90.4%—0.2%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$17.79M USD-246.0%-9.7%0.4%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$14.1M USD-191.6%—0.4%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$10.4M USD+168.0%—0.4%
AVTRAvantor, Inc.LTM Jun 2026$8M USD-205.3%—0.1%
STVNStevanato Group S.p.A.LTM Jun 2026€3.41M EUR-95.9%+75.4%0.3%
AZTAAzenta, Inc.LTM Sep 2026$2.58M USD-172.2%—0.4%
RGENRepligen CorporationLTM Jun 2026$2.51M USD-172.1%—0.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding AVTR) —-136.1%+32.8%0.4%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income572.6M686.5M321.1M711.5M(530.2M)
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
Deferred Income Tax(17.7M)(69.1M)(172.4M)(46.9M)7.7M
Stock-Based Compensation50.7M45.8M40.5M46.8M46.4M
Change in Working Capital(114.5M)(321.3M)16.6M47.7M(198.9M)
Accounts Receivables(111.8M)(45.2M)77M45.9M13.6M
Inventory(129.8M)(112.5M)30.3M(18.5M)(109.4M)
Accounts Payables64.9M15.6M(139.6M)59.6M42.4M
Other Working Capital62.2M(179.2M)48.9M(39.3M)(145.5M)
Other Non-Cash Items83.3M96.2M261.9M(323.8M)888.6M
Operating Cash Flow953.6M843.6M870M840.8M623.8M
Capital Expenditures(111.1M)(133.4M)(146.4M)(148.8M)(128.8M)
Acquisitions (Net)(4.01B)(20.2M)000
Purchases of Investments00000
Sales of Investments042.5M000
Other Investing Activities3.5M1.5M2.7M587.7M(1.7M)
Investing Cash Flow(4.12B)(109.6M)(143.7M)438.9M(130.5M)
Debt Repayment2.3B(620.4M)(846M)(1.34B)(318.7M)
Common Stock Issued967M0005.1M
Common Stock Repurchased(25.8M)(13.2M)(13.7M)(8.6M)(80.7M)
Dividends Paid(64.6M)(32.4M)000
Other Financing Activities41.9M17.3M16M69.2M(15.1M)
Financing Cash Flow3.22B(648.7M)(843.7M)(1.28B)(409.4M)
Effect of Forex Changes(13.2M)(15.5M)8.2M(21.5M)19.7M
Net Change in Cash37.9M69.8M(109.2M)(23M)103.6M
Free Cash Flow842.5M710.2M723.6M692M495M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.